A more recent study, which used a Quantitative Systems Pharmacology model to explore hemostatic equivalency of AT lowering, indicated that in a virtual population with severe hemophilia A, targeted AT levels of 15% to 35% result in a peak thrombin levels similar to that associated with 20% to 40% of FVIII activity [45]. The gene discussed is F8; the disease is hemophilia A.